Dihydroartemisinin Inhibits the Proliferation, Colony Formation and Induces Ferroptosis of Lung Cancer Cells by Inhibiting PRIM2/SLC7A11 Axis
Authors:
Open Access
- 1 October 2020
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 10829-10840
Abstract
Objective: Lung cancer is the first leading cause of cancer-related deaths both worldwide and in China and threatens human health and quality of life. New drugs and therapeutic methods are urgently needed. Our study evaluated the roles of dihydroartemisinin (DHA) in lung cancer and further explored its underlying mechanisms. Methods: CCK-8, colony formation and trypan blue exclusion assays were used to detect the cell viability, colony formation ability and cell death. qRT-PCR and Western blotting assays were applied to analyze the expressions of key molecules. Results: DHA inhibited the proliferation and colony formation abilities and enhanced the cell death and induced ferroptosis of lung NCI-H23 and XWLC-05 cancer cells. DHA reduced PRIM2 expression and silencing PRIM2 mimicked the inhibitory roles on proliferation and colony formation and promotive roles on cell death and ferroptosis of DHA in lung NCI-H23 and XWLC-05 cancer cells. We further found that DHA treatment and loss of PRIM2 reduced the GSH level and increased the cellular lipid ROS and mitochondrial MDA levels, and further downregulated the expressions of SLC7A11 and β-catenin in lung cancer cells, respectively. Exogenetic overexpression of PRIM2 recovered the inhibitory effects of DHA on proliferation and colony formation in lung NCI-H23 cancer cells, meanwhile loss of PRIM2 sensitizes NCI-H23 cells to DHA therapy. In vivo experiment further showed that DHA treatment significantly suppressed the tumor growth and downregulated PRIM2 and SLC7A11. Conclusion: Our study suggested that DHA inhibited the proliferation, colony formation and enhanced cell death and induced ferroptosis of lung cancer cells by inactivating PRIM2/SLC7A11 axis. Loss of PRIM2 induced ferroptosis might developed to be a novel therapeutic method in lung cancer therapy.Keywords
This publication has 48 references indexed in Scilit:
- Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1PLOS ONE, 2012
- Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer DrugJournal of Biomedicine and Biotechnology, 2011
- XRCC1 interacts with the p58 subunit of DNA Pol α-primase and may coordinate DNA repair and replication during S phaseNucleic Acids Research, 2009
- Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathwayOncogene, 2008
- DNA primase acts as a molecular brake in DNA replicationNature, 2006
- Assessment of F-MuLV-induced tumorigenesis reveals new candidate tumor genes including Pecam1, St7, and Prim2Leukemia, 2005
- Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compoundsExpert Opinion on Therapeutic Targets, 2005
- Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous ironFree Radical Biology and Medicine, 2004
- Assignment of the 49-kDa (PRIM1) and 58-kDa (PRIM2A and PRIM2B) Subunit Genes of the Human DNA Primase to Chromosome Bands 1q44 and 6p11.1-p12Genomics, 1995
- Transferrin receptor: Its biological significanceThe Journal of Membrane Biology, 1985